CClinicalTrials.gg
CompletedNCT03468348Updated Jun 24, 2020

Duloxetine for Acute Post-mastectomy Pain

An interventional study of Duloxetine in Acute Pain, sponsored by Assiut University. Completed at 1 site in Egypt. Open to female participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-06-24.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
Female
01

Study summary

The objective of this study is to evaluate the analgesic effect of oral dulexitine tablet (administered 2 h before surgery) as well as the ideal dose for acute postmastectomy pain.

Read the detailed description

patients undergoing mastectomy with axillary evacuation will be divided to four groups, Placebo group: received placebo capsule Duloxetine 30: received duloxetine 30 mg capsule Duloxetine 60: received duloxetine 60 mg capsule Duloxetine 90: received duloxetine 90 mg capsule the study medication is administered orall 2 h before surgery. Primary outcome variable: the first postoperative 24 h morphine consumption Secondary outcome: the VAS pain score measured every 4 h in the first 24 h postoperatively.

02

Conditions studied

  • Acute Pain

Browse trials for

Keywords

  • duloxetine
  • mastectomy
  • postoperative pain
03

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Adult females scheduled for unilateral MRM with axillary evacuation for breast cancer,
  • American Society of Anesthesiologists physical status (ASA) class I and II

Exclusion criteria

Exclusion Criteria:

  • Patients with a known allergy to Duloxetine or morphine,
  • A history of drug or alcohol abuse,
  • Patients with impaired kidney or liver functions,
  • Patients with chronic pain or regularly receiving analgesics,
  • Any psychiatric illness that would interfere with the perception and the assessment of pain.
  • Any reason that resulted in the protocol violation.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Placebo comparator
    placebo group

    Drug: Duloxetine

  • Active comparator
    duloxetine 30

    Drug: Duloxetine

  • Active comparator
    duloxetine 60

    Drug: Duloxetine

  • Active comparator
    duloxetine 90

    Drug: Duloxetine

Interventions

  • DrugDuloxetine

    patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.

05

What researchers measure

Primary outcomes

  1. the first postoperative 24 h (patient controlled analgesia [PCA])morphine consumption

    the cumulative patient controlled analgesia morphine consumption required by the patients to relieve their pain in the first postoperative 24 h

    Time frame: the first postoperative 24 hour

Secondary outcomes

  1. The intensity of pain measured by visual analogue pain scale (VAS)

    The intensity of pain measured by visual analogue pain scale (VAS) in which 0 = no pain and 10 = the maximum imaginable pain

    Time frame: The outcome will be assessed at 0 hour, 2 hour, 4 hour,8 hour, 16 hour and 24 hour postoperatively.

  2. The quality of postoperative recovery, assessed by "The QoR-40 questionnaire" (the quality of recovery-40 questionnaire)

    It measures five components of patient recovery: physical comfort (12 questions), physical independence (5 questions), emotional state (9 questions), psychological support (7 questions), and pain (7 questions). The sum of each component generates an aggregate score that ranges from 40 (i.e., extremely poor quality of recovery) to 200 (i.e., excellent quality of recovery)

    Time frame: the questionnair will be assessed once, 24 hour postoperatively

  3. The level of consciousness assessed by "the Modified Ramsay Sedation score"

    awake levels were: I = anxious, agitated, or restless; II = cooperative, oriented, and tranquil; III = responds to command, and asleep levels were dependent on patient's response to a light glabellar tap or loud auditory stimulus; IV= brisk response; V = a sluggish response; and VI = no response)

    Time frame: the score will be measured at 8 hour, 16 hour and 24 hour postoperatively

  4. The occurrence of vomiting

    vomiting is forceful discharge of stomach contents

    Time frame: The outcome will be obtained once 24 hour postoperatively

06

Study locations

1 site
  • Diab
    Assiut, Assuit 71515, Egypt
07

References and documents

Publications

  • Hetta DF, Elgalaly NA, Hetta HF, Fattah Mohammad MA. Preoperative Duloxetine to improve acute pain and quality of recovery in patients undergoing modified radical mastectomy: A dose-ranging randomized controlled trial. J Clin Anesth. 2020 Dec;67:110007. doi: 10.1016/j.jclinane.2020.110007. Epub 2020 Aug 22. PubMed 32847776 ↗
08

Registry details

Key details

Study ID
NCT03468348
Lead sponsor
Assiut University
Responsible party
Diab Fuad Hetta (principle investigator, Assiut University) — Principal investigator
First posted
Mar 16, 2018
Start date
Apr 1, 2018
Primary completion
Feb 10, 2020
Completion
Feb 10, 2020
Last update
Jun 24, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion